The Food and Drug Administration in May 2011 approved the first new drug in 25 years to treat diarrhea caused by Clostridium difficile, a pathogen that one study suggests may have surpassed methicillin-resistant Staphylococcus aureus as the leading hospital-acquired infection, according to the New York Times.
